- Home
- AXSM vs SNN Comparison
AXSM vs SNN Comparison
Compare AXSM & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | SNN |
|---|---|---|
| Founded | 2012 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.3B |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AXSM | SNN |
|---|---|---|
| Price | $156.47 | $27.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 6 |
| Target Price | ★ $283.63 | $32.32 |
| AVG Volume (30 Days) | 704.9K | ★ 1.2M |
| Earning Date | 11-02-2026 | 08-04-2026 |
| Dividend Yield | N/A | ★ 2.76% |
| EPS Growth | ★ 38.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.70 | $4.89 |
| Revenue Next Year | $60.69 | $5.25 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $123.42 | $26.30 |
| 52 Week High | $260.19 | $37.51 |
Technical Indicators
Market Signals| Indicator | AXSM | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 17.69 | 55.71 |
| Support Level | $152.83 | $27.23 |
| Resistance Level | $169.11 | $31.36 |
| Average True Range (ATR) | 6.21 | 0.40 |
| MACD | -2.38 | 0.19 |
| Stochastic Oscillator | 1.41 | 98.79 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.